Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

Scientists designed B7-H3-specific chimeric antigen receptor (CAR) T cells, confirmed their preclinical efficacy, and opened BrainChild-03, a first-in-human Phase I trial employing repeated locoregional B7-H3CARs to children with recurrent/refractory central nervous system tumors and diffuse intrinsic pontine glioma.